Clinical Trial Investigating the Efficacy of the Supera Peripheral Stent System for the Treatment of the Common Femoral Artery (VMI-CFA)

• ClinicalTrials.gov Identifier: NCT02804113
• Recruitment Status: Completed
• First Posted: June 17, 2016
• Last Update Posted: January 6, 2021
• Sponsor: ID3 Medical
• Information provided by (Responsible Party): ID3 Medical

Study Description

Brief Summary:

The VMI-CFA study investigates the efficacy of the Supera Stent in the treatment of common femoral artery stenosis or occlusion. 100 patients will be included with a RF of 2 to 4. The lesion is located within the native CFA and treated with predillation prior to stenting with the Supera Peripheral Stent System. Patients will be invited for a follow-up visit at 1, 6, 12 and 24 month post procedure. The primary endpoint of the study is the primary patency at 12 months and periprocedural events up to 30 days post procedure. Secondary endpoints include technical success, primary patency rate at 1, 6 and 24 month, freedom from TLR at 1-, 6-, 12 and 24 month follow-up and clinical success at 1-, 6-, 12- and 24-month follow-up.

Condition or disease	Intervention/treatment	Phase
Peripheral Arterial Disease	Device: Supera Peripheral Stent System	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 100 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: VMI-CFA Study: Physician-initiated Trial Investigating the Efficacy of the Vascular Mimetic Implant Supera Peripheral Stent System for the Treatment of the Common Femoral Artery
• Actual Study Start Date: April 25, 2016
• Actual Primary Completion Date: June 30, 2018
• Actual Study Completion Date: October 30, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Supera Peripheral Stent System	Device: Supera Peripheral Stent System

Outcome Measures

Primary Outcome Measures :

1. Primary patency at 12 months [ Time Frame: 12 months ]
   freedom from > 50% restenosis as indicated by an independently verified duplex ultrasound peak systolic velocity ratio (PSVR) <2.5 in the target vessel with no reintervention (TLR) within 12 months.
2. Periprocedural adverse events [ Time Frame: 30 days post procedure ]
   periprocedural adverse events up to 30 days post procedure, as defined per ISO 14155:2011

Secondary Outcome Measures :

1. Technical success [ Time Frame: during indexprocedure ]
   ability to cross and stent the lesion to achieve residual angiographic stenosis no greater than 30% and residual stenosis less than 50% by duplex imaging.
2. Primary patency rate at 1, 6 and 24 month [ Time Frame: 1, 6 and 24 month post procedure ]
   freedom from >50% restenosis as indicated by an independently verified duplex ultrasound peak systolic velocity ratio (PSVR) <2.5 in the target vessel with no intervention within 1 and 6 months.
3. Freedom from TLR until 24 month post procedure [ Time Frame: until 24 month post procedure ]
   freedom from a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge at the respective time points
4. Clinical success [ Time Frame: 1, 6, 12 and 24 month follow-up ]
   an improvement of Rutherford classification at 1-, 6-, 12- and 24-month follow-up of one class or more as compared to the pre-procedure Rutherford classification.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patient presenting a score from 2 to 4 following Rutherford classification
• Patient is willing to comply with specified follow-up evaluations at the specified times
• Patient is >18 years old
• Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
• Patient has a projected life expectancy of at least 12 months
• Prior to enrolment, the guidewire has crossed target lesion
• De novo lesions located in the common femoral artery, suitable for endovascular therapy
• The target lesions are located within the native CFA: localized between the origin of the circumflex iliac artery and the proximal (1cm) superficial femoral artery.
• There is angiographic evidence of a patent deep femoral artery
• The target lesion has angiographic evidence of stenosis > 50% or occlusion
• There is angiographic evidence of at least one-vessel-runoff to the foot, irrespective of whether or not outflow was re-established by means of previous endovascular intervention

Exclusion Criteria:

• Presence of another stent in the target vessel that was placed during a previous procedure
• Previous open surgery in the same limb
• Patients contraindicated for antiplatelet therapy, anticoagulants or thrombolytics.
• Patients who exhibit persistent acute intraluminal thrombus at the target lesion site.
• Perforation at the angioplasty site evidenced by extravasation of contrast medium
• Patients with known hypersensitivity to nickel-titanium and heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
• Patients with uncorrected bleeding disorders
• Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding
• Ipsilateral inflow (aorto-iliac) artery treatment before target lesion treatment with a residual stenosis>30%
• Use of thrombectomy, atherectomy or laser devices during procedure
• Any planned surgical intervention/procedure 30 days after the study procedure
• Any patient considered to be hemodynamically unstable at onset of procedure
• Patient is currently participating in another investigational drug or device study that has not reached the primary endpoint.
• Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc.) or other medical condition that would preclude compliance with the study protocol or 1-year life expectancy
• Major distal amputation (above the transmetatarsal) in the study limb or non-study limb
• Septicemia or bacteremia
• Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure

Contacts and Locations

Locations

Belgium

ZNA Stuivenberg

Antwerpen, Antwerp, Belgium, 2060

OLV Ziekenhuis Aalst

Aalst, Oost-Vlaanderen, Belgium, 9300

AZ Sint-Blasius

Dendermonde, Oost-Vlaanderen, Belgium, 9200

Imelda Hospital

Bonheiden, Belgium, 2820

France

Clinique Rhone Durance

Avignon, France, 84000

CHU de Clermont-Ferrand

Clermont-Ferrand, France, 63003

CHU de Nantes

Nantes, France, 44093

Sponsors and Collaborators

ID3 Medical

Investigators

• Study Director: Koen Deloose, MD; ID3 Medical

More Information

• Responsible Party: ID3 Medical
• ClinicalTrials.gov Identifier: NCT02804113
• Other Study ID Numbers: iD3 Medical - 160226
• First Posted: June 17, 2016
• Last Update Posted: January 6, 2021
• Last Verified: January 2021

Additional relevant MeSH terms:

Peripheral Arterial Disease; Peripheral Vascular Diseases; Atherosclerosis; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases